Reformulated imatinib eliminates morphine tolerance in lab studies
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats – an important step toward improving the effectiveness of chronic pain management in patients, according ...
Medications
Feb 21, 2012 |
4.8 / 5 (5) |
3
|
Cancer drug a possible treatment for multiple sclerosis
(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, which ...
Medical research
Feb 21, 2013 |
4 / 5 (1) |
0
|
Existing drugs offer new treatment options for high-risk childhood leukemia subtype
Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.
Cancer
Aug 13, 2012 |
not rated yet |
0
|
Multi-tasking imatinib boosts radiotherapy for bladder tumours
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.
Cancer
Mar 04, 2013 |
not rated yet |
0
Regorafenib active in metastatic GI stromal tumors
(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, ...
Cancer
May 23, 2012 |
not rated yet |
0
To prevent leukemia's dreaded return, go for the stem cells
Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out ch ...
Cancer
Apr 05, 2012 |
4.7 / 5 (3) |
0
Targeted drug helps leukemia patients who do not benefit from initial therapy
A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online ...
Cancer
Feb 27, 2012 |
5 / 5 (1) |
0
The race against chronic myeloid leukemia not yet won
Although significant progress has been made in treating chronic myeloid leukemia, the disease cannot yet be eliminated in all patients, and that challenge must be addressed, states a commentary in CMAJ (Canadian Medical A ...
Cancer
Jan 23, 2012 |
not rated yet |
0
Scientists discover how to beat resistance to standard leukaemia drug
(Medical Xpress) -- Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according ...
Cancer
Dec 09, 2011 |
5 / 5 (1) |
0
Gleevec's latest approval is for pediatric cancer
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Cancer
Jan 25, 2013 |
not rated yet |
0
Toward a more efficient therapy for a specific form of leukemia
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius ...
Cancer
Jun 14, 2011 |
5 / 5 (1) |
0
